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Atrial ﬁbrillation (AF) is the most common sustained cardiac ar-
rhythmia and can lead to the development of atrial thrombi. Although
vitamin K antagonists (like warfarin) are the only oral anticoagulant
therapy currently available, they have a narrow therapeutic index and
require the routine monitoring of coagulation. Recently, new oral anti-
coagulants (NOACs; rivaroxaban, apixaban, edoxaban and dabigatran)
have become available worldwide and do not require routine coagula-
tion monitoring. NOACs have been shown to be not inferior to warfarin
with regard to incidence of stroke, systemic embolism as the primary
endpoint andmajor bleeding [1–3]. Although routine coagulationmon-
itoring is not needed for NOAC, it would be useful to understand the cir-
cadian variation in the anticoagulant ability of NOAC, since their
anticoagulant effect may decrease quickly.
A novel automatedmicrochip ﬂow-chamber systemhas recently be-
come available for the quantitative evaluation of thrombus formation
under blood ﬂow conditions [T-TAS®, Total Thrombus-formation Anal-
ysis System, Fujimori Kogyo Co. Ltd., Tokyo, Japan] [4,5]. This system
may be suitable for assessing the anticoagulant effects of various thera-
pies, such as NOAC. Therefore, we assessed the anticoagulant effect of
rivaroxaban using this system in a patient with paroxysmal AF (PAF).A. Before B. 2 h C
Fig. 1.White thrombus formation on tissue thromboplastin- and collagen-coated AR-microchip
23 (D) h after the administration of rivaroxaban were loaded into the ﬂow-chamber system, a
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and was admitted to our University Hospital. He had suffered from pal-
rate because of PAF. He had a history of hypertension and prostatic hy-
pertrophy, and received azilsartan and tamsulosin and had just started
to take rivaroxaban. His blood pressure and heart rate at rest were
107/70 mm Hg and 54 beats/min, respectively. An electrocardiogram
showed a PAF, normal axis and no signiﬁcant ST–T changes during pal-
pitation. Chest X-ray showed cardiomegaly (the cardiothoracic ratio
was 57%). Transthoracic echocardiogram showed normal left ventricu-
lar (LV) systolic function (LV ejection fraction was 68%), only mild mi-
tral (I–II°) and tricuspid (I°) regurgitation, and mild left atrium
dilatation (40.8 mm). Prothrombin time-international normalized
ratio (PT-INR) and activated partial thromboplastin time (APTT) were
1.13 and 31.2 s, respectively.
The main purpose of this study was to conﬁrm the circadian varia-
tion in the anticoagulant effect of rivaroxaban using an automated mi-
crochip ﬂow-chamber system. We measured the effects before and 2,
4, 8, 11 and 23 h after the oral administration of 15 mg rivaroxaban
(Figs. 1 and 2). Our protocol was approved by the hospital ethics
committee.The procedure used for blood samplingwas explained in de-
tail to the patient and he provided his written informed consent. We
used two types of microchip, “AR-chip” and “PL-chip”, to evaluate
thrombus formation. The AR-chip can quantify white thrombus forma-
tion mediated through the activation of both platelets and the coagula-
tion system. The PL-chip can quantify platelet thrombus formation,
which involves platelet adhesion and aggregation, granule secretion,
and thrombus growth [4,5]. Whole blood was perfused at ﬂow rates of
4 μg/ml (AR-chip) and 18 μg/ml (PL-chip), corresponding to the initial
shear rates of 240/s and 1500/s. We deﬁned the parameters [T10, T60
or T80 (time to reach 10 kPa, 60 kPa or 80 kPa ﬂow pressure) and
AUC10 or 30 (area under the ﬂow pressure curve to quantify
thrombogenicity for the ﬁrst 10 or 30 min)] that we used to quantify. 11 h D. 23 h
s of the ﬂow-chamber system. Samples of blood collected before (A) and 2 (B), 11 (C) and
nd images of the microchip surfaces were then captured 5 min after the assay began.
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Fig. 2. Time courses of white thrombus formation (A, AR-T10 and AR-T80; B, AR-AUC30), platelet thrombus formation (C, PL-T10 and PL-T60), and activated clotting time (D, ACT) before
and 2, 4, 8, 11 and 23 h after the administration of rivaroxaban.
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fore the administration of rivaroxaban, AR-T10, AR-T80, AR-AUC30,
PL-T10, PL-T60, and PL-AUC10 were 8.18 min, 12.9 min, and 1565
(AU, arbitrary unit), and 200 s, 435 s and 284 AU, respectively
(Fig. 2A–C). Hosokawa and co-workers reported that the average values
of AR-T10, AR-T80 and AR-AUC30 in healthy volunteers were 8.8 ±
1.6 min, 14.2 ± 1.9 min, and 1503.5 ± 165.8 AU, respectively [4,5].
AR-T10, AR-T80 and AR-AUC30 in our patient were comparable to
those in healthy volunteers. As shown in Fig. 2, the peak times of AR-
10 and AR-80 after the administration of rivaroxaban were 4 or 11
and 2 h, respectively, and the effects persisted for up to 11 h. In addition,
AR-AUC30 showed a signiﬁcant reduction 2 h after the administration
of rivaroxaban and this trend also continued for 11 h. Although the
maximum plasma concentration was achieved after 3–4 h and the ter-
minal half-life was 5.7–9.2 h after the administration of rivaroxaban in
healthy male subjects [6], rivaroxaban continued to have an anticoagu-
lant effect up to at least 11 h after oral administration in this case. More
interestingly, this anticoagulant effect was completely absent the next
morning.
Since warfarin has a long half-life (36 h), it continues to have an an-
ticoagulant effect even long after it is discontinued. On the other hand,
while NOAC is effective immediately after administration, this effect is
lost relatively soon after it is discontinued. Although dabigatran and
apixaban need to be administered twice a day, rivaroxaban can be
used once a day. In the present case, once-daily administration of
rivaroxaban provided an adequate anticoagulant effect, which disap-
peared by the next morning. Once-daily intermittent anticoagulation
therapy with rivaroxaban may suppress the continuous activation of
thrombin, by preserving the activity of coagulation inhibitors, such as
tissue factor pathway inhibitor, antithrombin, protein C, protein S and
the ﬁbrinolytic system, and thus may prevent thrombus formation [7,
8]. In fact, in this case, there was no change in the activity of protein C
betweenbefore (87%) and 3 and 6 h (84% and 85%) after the administra-
tion of rivaroxaban. The maximum activated clotting time (ACT) was
2–4 h after the administration of rivaroxaban, and ACT returned to the
basal level 8 h after administration (Fig. 2D). Kubitza et al. reportedthat PT-INR and APTT peaked immediately after the administration of
rivaroxaban and returned to their basal levels 12 h after administration,
whereas the effects of rivaroxaban on anti-Factor Xa activity persisted at
more than 10% of the peak value during the trough phase [9]. This could
explain why the anticoagulant effect of rivaroxaban remained steady
evenwhen the values of ACT, PT-INR and APTT returned to their respec-
tive basal levels (during the trough phase) after the administration of
rivaroxaban.
In conclusion, this is the ﬁrst report of the use of an automated
microchip ﬂow-chamber system to assess the circadian variation in
the anticoagulant effect of rivaroxaban in a patientwith PAF. The further
analysis of such patients with PAF using an automated microchip ﬂow-
chamber system is warranted.Conﬂicts of interest
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